Founded Year

2014

Stage

Series F | Alive

Total Raised

$1.353B

Last Raised

$254M | 2 yrs ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+29 points in the past 30 days

About Freenome

Freenome operates as a biotechnology company specializing in early cancer detection within the healthcare sector. The company develops blood tests that use multiomics technology and artificial intelligence to identify cancer at its earliest and most treatable stages. It was founded in 2014 and is based in Brisbane, California.

Headquarters Location

3300 Marina Boulevard 5th Floor

Brisbane, California, 94005,

United States

650-446-6630

Loading...

ESPs containing Freenome

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare & Life Sciences / Monitoring, Imaging & Diagnostics Tech

The liquid biopsy cancer screening market offers a non-invasive alternative to traditional tissue biopsies for detecting cancer. This market includes various solutions such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) tests, which can detect cancer at an early stage and monitor treatment effectiveness. The liquid biopsy method is less invasive, faster, and more cost-effectiv…

Freenome named as Challenger among 15 other companies, including Roche, Becton Dickinson, and Exact Sciences.

Loading...

Research containing Freenome

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Freenome in 8 CB Insights research briefs, most recently on Jan 16, 2025.

Expert Collections containing Freenome

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Freenome is included in 8 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

1,287 items

A

AI 100 (All Winners 2018-2025)

99 items

Winners of CB Insights' annual AI 100, a list of the 100 most promising AI startups in the world.

C

Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare

D

Digital Health 50

300 items

The most promising digital health startups transforming the healthcare industry

D

Digital Health

11,440 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

P

Precision Medicine Tech Market Map

160 items

This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.

Freenome Patents

Freenome has filed 22 patents.

The 3 most popular patent topics include:

  • molecular biology
  • oncology
  • cancer screening
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/18/2023

3/11/2025

Clusters of differentiation, Blood tests, Blood, Immunology, Cell biology

Grant

Application Date

8/18/2023

Grant Date

3/11/2025

Title

Related Topics

Clusters of differentiation, Blood tests, Blood, Immunology, Cell biology

Status

Grant

Latest Freenome News

AI in genomics market to reach $9,859.7 million by 2031, registering a CAGR of 40.6%

Sep 15, 2025

machine learning (ML) techniques to analyze and interpret genomic data. Genomics is the study of DNA sequences and how they relate to an organism's traits, diseases, and potential treatments. AI and ML techniques can help scientists and researchers analyze large amounts of genomic data more efficiently and accurately, potentially leading to new discoveries and advancements in personalized medicine. The market for AI in genomics includes companies that provide software, platforms, and services for genomic data analysis, as well as companies that develop AI-powered diagnostics and therapeutics based on genomic data. According to the report, the global AI in genomics industry generated $346.3 million in 2021, and is anticipated to generate $9.8 billion by 2031, witnessing a CAGR of 40.6% from 2022 to 2031. Request a Sample Copy of the Research Report: https://www.alliedmarketresearch.com/request-sample/11921 The AI in genomics market can be segmented into various categories, including: Genomic Data Analysis: Companies that provide software, platforms, and services for genomic data analysis, including data preprocessing, quality control, alignment, variant calling, and functional annotation. Personalized Medicine: Companies that develop AI-powered diagnostics and therapeutics based on genomic data, including identifying genetic mutations that are associated with specific diseases and developing personalized treatment plans for patients. Drug Discovery and Development: Companies that use AI and ML techniques to accelerate the drug discovery and development process, including identifying drug targets, designing molecules, predicting drug efficacy and toxicity, and optimizing clinical trial design. Clinical Genomics: Companies that provide AI-powered solutions for clinical genomics applications, including genomic diagnostics, prognostics, and therapeutics. Agriculture and Livestock: Companies that use AI and genomics to improve crop yields, develop new crop varieties, and breed healthier livestock. Consumer Genomics: Companies that provide direct-to-consumer genetic testing services, including ancestry testing, disease risk assessment, and lifestyle recommendations. These segments are not mutually exclusive, and some companies may operate across multiple segments in the AI in genomics market. Covid-19 scenario: The outbreak of the Covid-19 pandemic had a negative impact on the global AI in genomics market, as it disrupted workflows in the healthcare sector around the world during the lockdown. The disease had forced several industries to shut down temporarily, including several sub-domains of the healthcare sector. The pandemic reduced accessibility to the research centers and offices which delayed the development in AI programs. However, AI-driven diagnostics emerged as great solution for quick diagnosis of the disease Procure Complete Report (220 Pages PDF with Insights, Charts, Tables, and Figures) @ https://www.alliedmarketresearch.com/purchase-enquiry/11921 Here are the top 10 key players in the AI in genomics market, based on their market share, revenue, and innovation: Illumina Inc. - A leading genomics company that offers genomic sequencing and array technologies for research, clinical, and applied markets. Qiagen N.V. - A provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. DNAnexus Inc. - A cloud-based platform for genomic data management, analysis, and collaboration. Freenome Holdings Inc. - A company developing an AI-powered blood test for early cancer detection. Sophia Genetics S.A. - A company offering AI-powered solutions for clinical genomics and precision medicine. Deep Genomics Inc. - A company using AI and genomics to develop new treatments for genetic diseases. Tempus Labs Inc. - A company using AI and machine learning to analyze and interpret clinical and genomic data for precision medicine. Fabric Genomics Inc. - A company providing AI-powered solutions for clinical genomics and drug discovery. Google LLC - A tech giant with various AI-powered genomics initiatives, including the Google Genomics platform and DeepVariant variant calling tool. Amazon Web Services (AWS) - A cloud computing provider that offers various genomic data management and analysis solutions, including the AWS Genomics service. Note that this list is not exhaustive, and there are many other companies and startups operating in the AI in genomics market. Request Customization: https://www.alliedmarketresearch.com/request-for-customization/11921 Based on region, North America held the highest market share in terms of revenue in 2021, accounting for nearly half of the global AI in genomics market, and is likely to dominate the market during the forecast period. This is attributed to a large number of universities and research institutions that are at the forefront of AI research, including Stanford, MIT, Carnegie Mellon University, and the University of California, Berkeley. These institutions attract top talent from around the world and conduct cutting-edge research. Furthermore, The U.S. government and private industry have invested heavily in AI research and development. However, the Asia-Pacific region is expected to witness the fastest CAGR of 46.9% from 2022 to 2031, owing to increase in investments for development of AI and an increase in the number of key players developing AI. Trending Reports in Healthcare Industry Brachytherapy Market https://www.alliedmarketresearch.com/brachytherapy-market-A11122 Plant Tissue Culture Market https://www.alliedmarketresearch.com/plant-tissue-culture-market-A14265 Knee Braces Market https://www.alliedmarketresearch.com/knee-braces-market-A10858 About Us: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. David Correa Allied Market Research email us here Visit us on social media: LinkedIn Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Freenome Frequently Asked Questions (FAQ)

  • When was Freenome founded?

    Freenome was founded in 2014.

  • Where is Freenome's headquarters?

    Freenome's headquarters is located at 3300 Marina Boulevard, Brisbane.

  • What is Freenome's latest funding round?

    Freenome's latest funding round is Series F.

  • How much did Freenome raise?

    Freenome raised a total of $1.353B.

  • Who are the investors of Freenome?

    Investors of Freenome include Andreessen Horowitz, DCVC, T. Rowe Price, RA Capital Management, Perceptive Advisors and 51 more.

  • Who are Freenome's competitors?

    Competitors of Freenome include Owlstone Medical, 20/20 BioLabs, BioTwin, GRAIL, Diagu and 7 more.

Loading...

Compare Freenome to Competitors

20/20 BioLabs Logo
20/20 BioLabs

20/20 BioLabs provides diagnostics for the healthcare sector, focusing on the detection and prevention of cancers and chronic diseases. The company offers laboratory-based blood tests that utilize machine learning algorithms to analyze real-world data, providing testing solutions. It serves individuals seeking health management and healthcare providers in need of diagnostic tools. 20/20 BioLabs was formerly known as 20/20 GeneSystems. It was founded in 2000 and is based in Gaithersburg, Maryland.

Owlstone Medical Logo
Owlstone Medical

Owlstone Medical focuses on breath analysis for disease detection within the healthcare sector. The company develops technology for discovering and validating biomarkers in breath, employing chemical analysis and sensor technology for diagnosis. Owlstone Medical's products and services are intended for academic, clinical, and pharmaceutical research partners involved in developing breath-based diagnostics. It was founded in 2004 and is based in Cambridge, United Kingdom.

O
OncoTAB

OncoTAb specializes in biotechnology with a focus on cancer diagnostic solutions. The company offers Agkura® Personal Score, a non-invasive blood test that measures tumor protein levels to aid in breast cancer detection. This test serves as a supplemental tool to mammography, which often misses cancers in women with dense breast tissue. It is based in Charlotte, North Carolina.

Accuragen Logo
Accuragen

AccuraGen develops liquid biopsy technology for the cancer diagnostics industry. The company provides services related to DNA and RNA sequencing to assist in treatment plans for cancer patients, emphasizing non-invasive diagnostic methods. AccuraGen serves the healthcare sector, particularly in oncology. It is based in Menlo Park, California.

L
Liquid Genomics

Liquid Genomics provides testing services for the detection of cancer gene mutations through blood-based testing within the healthcare and biotechnology sectors. The company utilizes digital PCR and allele-specific blocker PCR technologies to identify and quantify mutations in blood or tissue samples. Its services are aimed at the healthcare industry, focusing on cancer diagnostics and research. It is based in Torrance, California.

A
Artificial Intelligence Expert

Artificial Intelligence Expert focuses on AI technologies related to early detection of cancer within the healthcare sector. The company provides tests that can identify various types of cancer with reported accuracy rates. It is based in Cluj-Napoca, Romania.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.